Two mRNA vaccines have been approved to lead the fight against COVID19. Both have been rapidly approved with Emergency Use Authorization, which does not build public trust. Ultimately compelling the vaccine hesitant to receive the vaccination may be the most significant hurdle in the process. The science is complete, now the challenge is public acceptance.  Today’s podcast is more detail on the vaccine, how it works, and the reasons for hesitancy.  The New England Journal of Medicine published clinical trials are described as well, along with strategies for effective communication. With Allison Kennedy and Dr. Asha Brunings# COLABRATalking Biotech is brought to you by Colabra – an R&D platform that brings your lab’s world-changing research together in one shared space. Learn more at https://www.colabra.app/# TALKING BIOTECHTwitter: https://twitter.com/talkingbiotechWebsite: https://www.colabra.app/podcasts/talking-biotech/Instagram: https://www.instagram.com/colabrahqThe Talking Biotech podcast is distinct from Dr. Kevin Folta's teaching and research roles at the University of Florida. The views expressed on the show are those of Dr. Folta and his guests, and do not reflect the opinions of the university or Colabra.